Erdark/E+ via Getty Images
- Teladoc Health (NYSE:TDOC) is up 8% in Tuesday afternoon trading after announcing it is launching provider-based care for weight management and prediabetes.
- Teladoc will provide customers with access to one of its physicians to develop a personalized care plan, as well as coaching and digital tools.
- The physicians can also prescribe weight loss and diabetes drugs, including glucagon-like peptide (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, if deemed appropriate.
- Novo Nordisk's (NVO) weight-loss therapy Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) are examples of GLP-1 agonists. Lilly (LLY) and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca's Farxiga (dapagliflozin) are SGLT2 inhibitors.
- The expansion into weight management and prediabetes will become available in Q3.
- Read why Seeking Alpha contributor Tangerine Capital considers Teladoc (TDOC) a buy.